Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ASLAN-004; CSL334; IL-13R; IL-13R - Merck; IL-13Rα1 project; MK 6105

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Zenyth Therapeutics
  • Developer ASLAN Pharmaceuticals; CSL; Merck & Co
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-13 receptor alpha1 subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Atopic dermatitis
  • No development reported Asthma

Most Recent Events

  • 02 Dec 2019 Preliminary efficacy and adverse events data from a phase I trial in Atopic dermatitis released by ASLAN Pharmaceuticals
  • 30 Sep 2019 ASLAN Pharmaceuticals initiates phase I multiple ascending dose (MAD) trail in Atopic dermatitis (In moderate to severe atopic dermatitis patients) in Singapore (SC) (NCT04090229)
  • 04 Jun 2019 ASLAN Pharmaceuticals plans a multiple ascending dose trial for in moderate to severe Atopic dermatitis in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top